Please ensure Javascript is enabled for purposes of website accessibility

New Breast Cancer Drug Could Transform Treatment

By Dave Williamson – Feb 4, 2014 at 10:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's why shares of Pfizer popped today.

Pfizer (PFE -0.35%) announced today a successful phase 2 trial of its breast cancer drug Palbociclib, which had shares up 2.5% on the news. "We are delighted with the final data, which suggests the potential for Palbociclib to transform the standard of care," Pfizer announced. The company could file for accelerated approval in March, which would potentially mean approval this year.

In this video, Motley Fool health-care analyst David Williamson looks at the competition in this space, the potential market for Pfizer's new drug, and one secret winner that stands to benefit here.

David Williamson owns shares of Novartis and Pfizer. The Motley Fool has no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$50.73 (-0.35%) $0.18
Eli Lilly And Stock Quote
Eli Lilly And
LLY
$369.29 (-1.46%) $-5.47
Novartis Stock Quote
Novartis
NVS
$90.96 (1.08%) $0.97

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.